Pharma BD Deal Intelligence
AstraZeneca acquired 55% of Acerta Pharma for $4B for BTK inhibitor.
AstraZeneca acquires 55% stake in privately-owned Acerta Pharma for $4 billion, with the agreement including options for AstraZeneca to buy the remaining…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AstraZeneca acquired 55% of Acerta Pharma for $4B for BTK inhibitor.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Acerta Pharma (this deal) | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2015 deals · AstraZeneca PLC deals · Oncology deals